SCENESSE

PeakPeptide

afamelanotide

NDASUBCUTANEOUSIMPLANTPriority Review
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Jan 20, 2033
83 months away
Patent Expiry
Jan 20, 2033
Exclusivity Expiry
Oct 8, 2026

Patent Records (1)

Patent #ExpiryTypeUse Code
8334265
Jan 20, 2033
U-2638
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers